Nightstar Therapeutics: Gene Therapy Play – Seeking Alpha
Seeking Alpha |
Nightstar Therapeutics: Gene Therapy Play
Seeking Alpha Over 90% of patients in an investigator-sponsored study maintained or improved their visual acuity when treated with NSR-REP1, adding to conviction of this promising gene therapy story. The company has other promising gene therapy candidates that … |
